Clinical trial register · China

Clinical Trials in Liuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC

19212

Studies in scope

all four open statuses

11805

Recruiting now

open to new participants

2029

Lead sponsors

across recruiting studies

Top sites

Beijing 47 Guangzhou 41 Shenzhen 19 Zhengzhou 19 Chongqing 18

Narrow the registerReset

Search within results

Recruitment status

Phase

Lead sponsor

Clear sponsor filter

Site location

All 67 locations

Target enrolment

Trials with a site in Liuzhou

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou

2024-10-07

Active, closed

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

NCT05664737Anemia

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 2

189

Guangzhou, Foshan, Maoming Shi, Shenzhen Shi, Liuzhou, Nanning, Haikou, Kunming

2022-12-09

Active, closed

A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.

NCT05567458Beta-thalassemia

DrugLuspatercept

Bristol-Myers Squibb

Phase 2

Maoming, Shenzhen, Liuzhou, Nanning, Haikou, Kunming, Guangzhou

2022-10-17

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/liuzhou

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3 of those studies with a site in Liuzhou that also match the filters currently applied.

How many clinical trials are recruiting in Liuzhou?

1 of the 3 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Liuzhou), 3 studies
Phase	Studies	Recruiting	Share
Phase 2	2	0	66.7%
Phase 3	1	1	33.3%

Most active sponsors

Lead sponsors with the most studies (Liuzhou)
Lead sponsor	Studies	Recruiting
Bristol-Myers Squibb	3	1

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.